LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

“Softer” Mass Spec Techniques Gain Advantage in Biomarker Discovery

By LabMedica International staff writers
Posted on 29 Mar 2015
Two mass spectrometry (MS) technologies, MALDI and DESI, are increasing in applications as their effectiveness is established, according to Kalorama Information (New York, NY, USA) in its report “Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies).”

MS is the most powerful tool in proteomic biomarker discovery and validation. Through its traditional techniques MS has struggled to elucidate tissue molecular distribution related to disease state. In recent years, MS imaging, including MALDI and DESI imaging, has seen significant application in proteomic biomarker discovery with its distinct advantages in preservation of spatial proteomic data and potential to improve assay reproducibility.

In MALDI and DESI, nondestructive techniques are utilized with soft ionization sources to desorb and ionize surface molecules for MS analysis. According to Kalorama, one of the key strengths of MALDI and DESI is that they avoid traditional tissue sample preparation, a tedious front-end process that presents a significant bottleneck in proteomics where differential analysis is used to compare protein expression and abundance between samples. Proteolytic digestion and other sample preparation procedures remove significant analytical context value related to protein spatial distribution and concentration.

Kalorama believes that a number of studies have cemented the reputation of these MS technologies. Researchers have noted the novelty of MALDI imaging of tissue (introduced in 1997) to discover proteins otherwise difficult to separate by electrophoresis or hidden in shotgun proteomic processes that are biased towards higher-mass proteins. Recent studies have used MALDI imaging to discover several biomarkers associated with gastric cancer survival prognosis, forms of ovarian cancer, and to develop a novel grading system for papillary non-invasive bladder cancer.

Kalorama’s report contains breakouts of the market by type of technology used and application. It profiles companies and surveys partnerships and deals related to proteomics.

Related Links:

Kalorama Information
Proteomics Markets for Research and IVD Applications, report


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Pan-Cancer Panel
TruSight Oncology 500

DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
PURITAN MEDICAL